List of Suboxone drug patents
Suboxone is owned by Indivior Inc.
Suboxone contains Buprenorphine Hydrochloride; Naloxone Hydrochloride.
Suboxone has a total of 8 drug patents out of which 3 drug patents have expired.
Expired drug patents of Suboxone are:
- US9855221
- US9931305
- US10285910
Suboxone was authorised for market use on 30 August, 2010.
Suboxone is available in film;buccal, sublingual dosage forms.
Suboxone can be used as this drug is administered by sublingual route to humans for maintenance treatment of opioid dependence, treatment of opioid dependence/sublingual or buccal application, treating opioid use disorder.
The generics of Suboxone are possible to be released after 26 March, 2030.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9855221 | INDIVIOR INC | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
Feb, 2022
(11 months ago) | |
| US9931305 | INDIVIOR INC | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
Feb, 2022
(11 months ago) | |
| US10285910 | INDIVIOR INC | Sublingual and buccal film compositions |
Oct, 2022
(3 months ago) | |
| US8017150 | INDIVIOR INC | Polyethylene oxide-based films and drug delivery systems made therefrom |
Feb, 2023
(13 days from now) | |
| US8603514 | INDIVIOR INC | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
Apr, 2024
(1 year, 2 months from now) | |
| US11135216 | INDIVIOR INC | Sublingual and buccal film compositions |
Aug, 2029
(6 years from now) | |
| US9687454 | INDIVIOR INC | Sublingual and buccal film compositions |
Aug, 2029
(6 years from now) | |
| US8475832 | INDIVIOR INC | Sublingual and buccal film compositions |
Mar, 2030
(7 years from now) | |
Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 August, 2010
Treatment: Treatment of opioid dependence/sublingual or buccal application; Treating opioid use disorder; This drug is administered by sublingual route to humans for maintenance treatment of opioid dependence
Dosage: FILM;BUCCAL, SUBLINGUAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic